In an interview with Targeted Oncology, Scott Tykodi, MD, PhD, a physician with the Seattle Cancer Care Alliance, and associate professor in the Division of Medical Oncology at University of Washington Medicine, and an associate professor in the Clinical Research Division at the Fred Hutchinson Cancer Research Center, discussed findings from the analysis from the KEYNOTE-427 trial in patients with ccRCC.
Updated follow-up of cohort A in the KEYNOTE-427 study indicated that pembrolizumab (Keytruda) monotherapy was tolerable with promising antitumor activity in patients with clear cell renal cell carcinoma (ccRCC). There was a trend towards improved overall survival (OS) among patients who had greater reductions in target lesions, as well.
The overall objective response rate (ORR) was 36.4% (95% CI, 27.4%-46.1%), which included 3 complete responses (CRs) and 37 partial responses. The median progression-free survival (PFS) was 7.1 months (95% CI, 5.6-11.0), and the median overall survival (OS) was not yet reached. The 18-month OS rate was 80.0% and the 18-month PFS rate was 26.6%.
Patients enrolled to this cohort had to have clear cell histology. These data were presented at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program, and a second study, a biomarker analysis on these data, was also presented at this year’s virtual meeting.
The objective of this research was to determine if there was an association between the depth of response and OS in cohort A. At the time of data cut-off, the median duration of response had not yet been reached.